Korro Bio, Inc.
KRRO · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.11 | -0.17 | 0.00 | 0.53 |
| FCF Yield | -16.51% | -15.04% | -2.63% | -6.75% |
| EV / EBITDA | -4.72 | -6.07 | -15.09 | -12.91 |
| Quality | ||||
| ROIC | -16.42% | -13.06% | -10.83% | -10.13% |
| Gross Margin | 17.81% | 100.00% | 100.00% | 0.00% |
| Cash Conversion Ratio | 0.95 | 0.75 | 1.05 | 0.35 |
| Growth | ||||
| Revenue 3-Year CAGR | 1,946,046.24% | 1,844,956.19% | 1,689,221.76% | 1,314,334.79% |
| Free Cash Flow Growth | 21.18% | -174.63% | 57.34% | -2.04% |
| Safety | ||||
| Net Debt / EBITDA | -0.41 | 0.80 | 0.50 | 0.96 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 67.13 | 67.91 | 67.21 | -619.08 |